STOCK TITAN

Aprea (APRE) grants director RSUs and 12,555 options at $0.7293

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Aprea Therapeutics, Inc. director Michael Grissinger received equity compensation in the form of restricted stock units and stock options. On June 16, 2026, he was granted 3,135 restricted stock units that will vest and be settled in common stock on June 16, 2027, if he continues serving on the board through that date.

He also received stock options for 12,555 shares of common stock at an exercise price of $0.7293 per share, vesting in full on June 16, 2027 and expiring on June 16, 2036, subject to the same service-based condition. After these grants, he directly holds 6,024 shares of common stock and 12,555 stock options.

Positive

  • None.

Negative

  • None.
Insider Grissinger Michael
Role null
Type Security Shares Price Value
Grant/Award Stock Options (Right to Buy) 12,555 $0.00 --
Grant/Award Common Stock 3,135 $0.00 --
Holdings After Transaction: Stock Options (Right to Buy) — 12,555 shares (Direct, null); Common Stock — 6,024 shares (Direct, null)
Footnotes (1)
  1. These shares represent restricted stock units which were granted on June 16, 2026, and which will vest and be settled in common stock on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. The option vests in full on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.
Restricted stock units granted 3,135 shares Granted June 16, 2026; vest June 16, 2027
Stock options granted 12,555 options Granted June 16, 2026; underlying common stock
Option exercise price $0.7293 per share Stock options granted June 16, 2026
Option expiration date June 16, 2036 Stock options for 12,555 shares
Common shares held after grants 6,024 shares Direct ownership following June 16, 2026 awards
Options held after grants 12,555 options Direct derivative holdings following the grant
restricted stock units financial
"These shares represent restricted stock units which were granted on June 16, 2026"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
vest financial
"which will vest and be settled in common stock on June 16, 2027"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
stock options financial
"The option vests in full on June 16, 2027"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
exercise price financial
"conversion_or_exercise_price": "0.7293""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date": "2036-06-16T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Grissinger Michael

(Last)(First)(Middle)
3805 OLD EASTON ROAD

(Street)
DOYLESTOWN PENNSYLVANIA 18902

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Aprea Therapeutics, Inc. [ APRE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/16/2026A3,135(1)A$0.006,024D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Options (Right to Buy)$0.729306/16/2026A12,555 (2)06/16/2036Common Stock12,555$0.0012,555D
Explanation of Responses:
1. These shares represent restricted stock units which were granted on June 16, 2026, and which will vest and be settled in common stock on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.
2. The option vests in full on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.
/s/ John Hamill, as Attorney-in-Fact06/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did Aprea Therapeutics (APRE) grant to director Michael Grissinger?

Aprea Therapeutics granted director Michael Grissinger 3,135 restricted stock units and stock options for 12,555 shares. The options carry a $0.7293 exercise price and both awards are subject to future vesting conditions tied to continued board service.

When do Michael Grissinger’s Aprea Therapeutics (APRE) restricted stock units vest?

Grissinger’s 3,135 restricted stock units vest and settle in common stock on June 16, 2027. Vesting requires his continued service on Aprea Therapeutics’ board of directors through and including that date, with potential acceleration only under specified conditions.

What are the key terms of Michael Grissinger’s Aprea Therapeutics (APRE) stock options?

He received options for 12,555 shares of Aprea common stock at a $0.7293 exercise price. These options vest in full on June 16, 2027, require continued board service, and expire on June 16, 2036 if not exercised earlier.

How many Aprea Therapeutics (APRE) shares does Michael Grissinger hold after these grants?

Following the June 16, 2026 grants, Grissinger directly holds 6,024 shares of Aprea common stock. In addition, he holds stock options covering 12,555 underlying shares that will vest in 2027, subject to continued service conditions.

Is Michael Grissinger’s Aprea Therapeutics (APRE) Form 4 transaction an open-market trade?

No, the Form 4 reports compensation-related equity awards, not open-market trades. The 3,135 restricted stock units and 12,555 stock options were granted at no cash cost to him, with vesting based on continued board service.